INS and metabolic syndrome: Agents that directly increase insulin signaling at IR or post‐IR levels, “insulin sensitizers,” or act like, but independently of, insulin intracellularly to reverse T2DM‐induced biochemical aberrations, “insulin mimickers,” would seem more logical, as insulin resistance is widespread, if not ubiquitous, in DIO/MetS/T2DM.